Abstract: A compact control device for failsafely controlling an electrical actuator capable of moving a movable machine part into a defined end position, has an input connection for receiving an external control signal representing a desired position of the machine part. The compact control device further has an input part for detecting a position signal, which signals an actual position of the machine part at the defined end position. A power section comprises a power switching element for switching on and failsafely switching off a control current for the actuator that is supplied to the electrical actuator via a first output connection. The compact control device has a second output connection for providing an external status signal and an evaluation unit which actuates the power switching element depending on the external control signal and generates the external status signal at the second output connection depending on the position signal.

Abstract: A compact control device for failsafely controlling an electrical actuator capable of moving a movable machine part into a defined end position, has an input connection for receiving an external control signal representing a desired position of the machine part. The compact control device further has an input part for detecting a position signal, which signals an actual position of the machine part at the defined end position. A power section comprises a power switching element for switching on and failsafely switching off a control current for the actuator that is supplied to the electrical actuator via a first output connection. The compact control device has a second output connection for providing an external status signal and an evaluation unit which actuates the power switching element depending on the external control signal and generates the external status signal at the second output connection depending on the position signal.

Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.

Abstract: The invention concerns the use of mercaptoethane sulfonate-sodium (Mesna) to increase the solubility of Ifosfamide in storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical preparations, storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical Ifosfamide preparations for parenteral administration as well as a process for their production.

Abstract: The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of an aqueous solution of an inorganic or acetic acid salt for producing a pharmaceutical administration form which releases peptides in a continuous manner over a long period of time.

Abstract: The invention at hand concerns trofosfamide containing film-coated tablets for oral application and a procedure for their production.

Abstract: The present invention relates to a pharmaceutical formulation for oral administration of the poorly soluble and therefore hardly bioavailable microtubule polymerization inhibitor Indibulin and a process for its manufacture. In particular, there is provided a pharmaceutical formulation of Indibulin for oral administration comprising a granulate containing micronized Indibulin having a particle size of less than 20 ?m for at least 99% of the volume of particles, at least one hydrophilic surfactant, and at least one capsulation excipient. The present invention also discloses a method of treating hyperproliferative disorders, malignancies and neoplasms with Indibulin.

Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.

Abstract: The invention relates to a pharmaceutical presentation form for the oral administration of indibulin in the form of an aqueous drink solution, and a method for its preparation.

Abstract: The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of an aqueous solution of an inorganic or acetic acid salt for producing a pharmaceutical administration form which releases peptides in a continuous manner over a long period of time.

Abstract: The invention concerns the use of mercaptoethane sulfonate-sodium (Mesna) to increase the solubility of Ifosfamide in storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical preparations, storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical Ifosfamide preparations for parenteral administration as well as a process for their production.